STOCK TITAN
  1. Home
  2. News
  3. BCTX

Briacell Therapeutics Corp. Common Shares - BCTX STOCK NEWS

Welcome to our dedicated page for Briacell Therapeutics Common Shares news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics Common Shares stock.

BriaCell Therapeutics Corp (NASDAQ: BCTX) is a pioneering biotechnology company headquartered in Los Angeles, specializing in the development of immunotherapy treatments for cancer management. The company’s innovative approach focuses on harnessing the body's immune system to target and eliminate cancer cells, providing new hope for patients battling this devastating disease.

Central to BriaCell's portfolio is the BriaVax vaccine, which has shown promising results in early-phase clinical trials. In two compelling FDA Phase I studies involving late-stage breast cancer patients, BriaVax demonstrated unique and unprecedented outcomes, showcasing its potential as a groundbreaking treatment. Building on these successes, BriaCell is aggressively advancing towards a Phase I/II clinical trial, aiming to expand its vaccine's application to a larger cohort of breast cancer patients.

In addition to BriaVax, the company is also developing Bria-IMT, currently in a Phase I/IIa clinical trial targeting metastatic breast cancer. Bria-IMT represents a targeted and safe approach to treating advanced-stage breast cancer, reinforcing BriaCell's commitment to innovative cancer therapies. Another significant development in their pipeline is the Bria-OTS ('off-the-shelf') personalized immunotherapy, designed to match the patient's HLA type, further customizing and enhancing the treatment's effectiveness.

While BriaCell's current focus remains on breast cancer, the company is exploring the potential of applying its vaccine technology to other cancer types, broadening its impact in the oncology field. With a strategic vision and robust pipeline, BriaCell is poised to make significant contributions to cancer treatment and patient care.

For more detailed updates and the latest news about BriaCell Therapeutics Corp, visit their website or contact them directly. The company remains committed to transparency and regularly shares progress on their groundbreaking research and clinical trials.

News

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Rhea-AI Summary
BriaCell Therapeutics Corp. (BCTX) reports significant reduction in metastatic breast cancer tumor behind the eye after 3 cycles of Bria-IMT™ combination regimen. The patient had failed 7 prior regimens, including antibody-drug conjugate therapy, and experienced reduced proptosis and ocular pain. Bria-IMT™ showed robust anti-tumor activity in difficult-to-reach tumors, with a 71% intracranial objective response rate in breast cancer patients with CNS metastases. The pivotal Phase 3 study in advanced breast cancer is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
-
News

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reports 71% intracranial objective response rate (iORR) in advanced breast cancer patients with CNS metastases treated with Bria-IMT™ regimen, demonstrating clinical efficacy and potential market approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
none
-
News

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen. Overall Survival (OS) data exceeded similar studies, with a median OS up to twice that reported in the literature. Progression Free Survival (PFS) was similar or better than the last regimen in 40% of the patients, and a disease control rate of 40% was observed in evaluable patients, further indicating clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
News

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated with Bria-IMT™ in combination with an immune check point inhibitor. The median overall survival was 13.4 months, a marked improvement over the benchmark of 6.7-9.8 months for similar patients. 32 out of 42 patients treated since 2022 remain alive, indicating consistently strong survival benefit. All patients were able to receive therapy with no toxicity-related discontinuations. The Phase 2 study is fully enrolled with 54 advanced metastatic breast cancer patients, showing excellent overall survival and tolerability, as well as a positive immune response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
News

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is presenting findings at the 2023 San Antonio Breast Cancer Symposium, demonstrating the effectiveness of their Bria-IMT™ combination regimen in activating cancer-fighting T cells and producing unique antibody responses in patients with disease control. Advanced CD8 ImmunoPET imaging showed the transformation of cold immune suppressed tumors to hot immune responsive ones, indicating the potential of the treatment in cancer patients. The company also plans to present updated overall survival clinical data, showing significant anti-tumor activity of Bria-IMT™ in advanced metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
News

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announces a remarkable responder in their Phase 2 study of the Bria-IMT™ combination regimen. A patient with extensive metastatic breast cancer behind the eye experienced a remarkable improvement of eye-bulging 'proptosis' and significant pain reduction after only 3 cycles of treatment. The patient had previously failed 7 regimens and continues to receive treatment. Additional survival updates and clinical data sets will be presented at the San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
none
News

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

Rhea-AI Summary
BriaCell reports unprecedented immune system activation in tumor models with its next generation breast and prostate cancer immunotherapies. The FDA has authorized BriaCell's Investigational New Drug Application (IND) for Bria-OTS™, opening the path to clinical trials. The company's immunotherapies have shown enhanced efficacy and safety profiles, with potential advantages including precision therapy, favorable safety profiles, rapid and cost-effective treatments, and potent immune system activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.41%
Tags
none
-
News

BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

Rhea-AI Summary
BriaCell Therapeutics Corp. announces the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) and a new member to its scientific advisory board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
management
-
News

October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

Rhea-AI Summary
BriaCell Therapeutics recognizes Breast Cancer Awareness Month and reports positive clinical results in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
none
News

BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

Rhea-AI Summary
BriaCell Therapeutics Corp. announces upcoming presentations at scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none

FAQ

What is the current stock price of Briacell Therapeutics Common Shares (BCTX)?

The current stock price of Briacell Therapeutics Common Shares (BCTX) is $0.7297 as of November 22, 2024.

What is the market cap of Briacell Therapeutics Common Shares (BCTX)?

The market cap of Briacell Therapeutics Common Shares (BCTX) is approximately 25.3M.

What does BriaCell Therapeutics Corp do?

BriaCell Therapeutics Corp specializes in developing immunotherapy treatments for cancer, focusing primarily on breast cancer.

What are the main products of BriaCell Therapeutics Corp?

BriaCell's main products include the BriaVax vaccine, Bria-IMT, and Bria-OTS, which are all designed to treat advanced-stage breast cancer.

What is BriaVax?

BriaVax is a patented vaccine developed by BriaCell for treating late-stage breast cancer, showing promising results in early clinical trials.

What clinical trials is BriaCell currently conducting?

BriaCell is conducting a Phase I/IIa clinical trial for Bria-IMT in metastatic breast cancer and is planning to launch a Phase I/II trial for BriaVax.

Where is BriaCell Therapeutics Corp headquartered?

BriaCell Therapeutics Corp is headquartered in Los Angeles, California.

Is BriaCell focusing only on breast cancer?

Currently, BriaCell's primary focus is on breast cancer, but the company is exploring the potential to apply its vaccine technology to other cancer types.

How can I contact BriaCell Therapeutics Corp?

You can contact BriaCell through their website or by reaching out to their President & CEO, Dr. William V. Williams, at 1-888-485-6340 or info@briacell.com.

What makes BriaCell's immunotherapy approach unique?

BriaCell's approach leverages the body's immune system to target cancer cells, with products like Bria-OTS offering personalized treatment by matching the patient's HLA type.

Who are the primary contacts for media and investor relations at BriaCell?

For media relations, contact Jules Abraham at CORE IR; for investor relations, contact CORE IR at investors@briacell.com.

Where can I find the latest news about BriaCell Therapeutics Corp?

The latest news about BriaCell can be found on their website and through regular updates provided via their press releases and news announcements.

Stock BCTX logo
Briacell Therapeutics Corp. Common Shares

Nasdaq:BCTX

BCTX Rankings

#5199 Ranked by Market Cap
N/A Ranked by Dividends

BCTX Stock Data

25.33M
29.09M
19.79%
13.01%
2.06%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WEST VANCOUVER